

Leonie I Kroeze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3672268/publications.pdf>

Version: 2024-02-01

24
papers

511
citations

687363

13
h-index

713466

21
g-index

25
all docs

25
docs citations

25
times ranked

1024
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal evolution in myelodysplastic syndromes. <i>Nature Communications</i> , 2017, 8, 15099.	12.8	118
2	Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 757-769.	2.8	42
3	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 136, 16-24.	2.8	41
4	Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. <i>Blood</i> , 2018, 131, 1846-1857.	1.4	35
5	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e7-729.e16.	1.6	34
6	Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. <i>International Journal of Cancer</i> , 2020, 146, 3196-3206.	5.1	28
7	Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. <i>Oncologist</i> , 2021, 26, e1347-e1358.	3.7	28
8	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin–based chemotherapy in metastatic castration–resistant prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 385-395.	5.1	28
9	Next-Generation Sequencing–Based Clonality Assessment of Ig Gene Rearrangements. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1105-1115.	2.8	25
10	Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 673-680.	2.8	24
11	Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation. <i>Pancreas</i> , 2020, 49, 999-1003.	1.1	20
12	A novel next generation sequencing approach to improve sarcoma diagnosis. <i>Modern Pathology</i> , 2020, 33, 1350-1359.	5.5	20
13	Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. <i>BMC Cancer</i> , 2020, 20, 291.	2.6	20
14	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. <i>Journal of Molecular Diagnostics</i> , 2022, 24, e004329.		15
15	Multiple Immunoglobulin κ Gene Rearrangements within a Single Clone Unraveled by Next-Generation Sequencing–Based Clonality Assessment. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1097-1104.	2.8	8
16	Unraveling Neuroendocrine Gallbladder Cancer: Comprehensive Clinicopathologic and Molecular Characterization. <i>JCO Precision Oncology</i> , 2021, 5, 473-484.	3.0	6
17	Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden. <i>Respiratory Research</i> , 2021, 22, 302.	3.6	5
18	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 907-916.	6.4	5

#	ARTICLE	IF	CITATIONS
19	Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.. Journal of Clinical Oncology, 2020, 38, 121-121.	1.6	3
20	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. Oncolmunology, 2022, 11, .	4.6	3
21	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Advances, 2021, 5, 3188-3198.	5.2	2
22	Which angiosarcoma subtypes may benefit from immunotherapy?. Journal of Clinical Oncology, 2022, 40, 11572-11572.	1.6	1
23	Genetic Diversity within Leukemia-Associated Immunophenotype-Defined Subclones in AML. Blood, 2021, 138, 3440-3440.	1.4	0
24	First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. Journal of Clinical Oncology, 2022, 40, 40-40.	1.6	0